Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2016-04-06 Call Transcript
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
CP Eng
Call Transcript Classification · 90% confidence The document is an announcement from AB Science regarding a live webcast scheduled for April 8, 2016, to discuss the phase 3 interim analysis results of masitinib in ALS treatment. It details the agenda for the webcast, including discussion points, participating Key Opinion Leaders (KOLs), and background information on the drug and the company. This is not a full financial report (like 10-K or IR), nor is it a formal earnings release (ER). It is an announcement about a specific event where results and analysis will be presented, which strongly aligns with the nature of a conference call or presentation event. Since it details an upcoming call with Q&A, the most appropriate classification is Call Transcript (CT), even though this document is the *announcement* of the call, not the transcript itself. However, given the options, and the focus on a detailed discussion/Q&A session about clinical results, it is closely related to the content discussed in a CT. If the document were the transcript itself, CT would be perfect. Since it is an announcement of a call that includes Q&A, it is a precursor to a CT. Given the options, and the fact that it is an announcement about a detailed discussion event, it is closest to a Call Transcript (CT) or potentially an Investor Presentation (IP) if it were a slide deck. Since it explicitly mentions a 'live webcast' followed by a 'Q&A session with the management,' it is most analogous to the content of a Call Transcript (CT). If 'RPA' (Report Publication Announcement) were used, it would imply the announcement of a formal report, whereas this announces a discussion event. Therefore, CT is the best fit for the nature of the event being announced.
2016-04-06 English
CP Eng
Earnings Release Classification · 95% confidence The document is an announcement from AB Science reporting positive interim results from a Phase 3 clinical trial for Masitinib in treating Amyotrophic Lateral Sclerosis (ALS). It details the study design, the success of the primary and secondary endpoints (p-values mentioned), and plans to discuss filing for marketing authorization with the EMA and FDA. This content is a direct communication of significant operational and clinical development news, which is characteristic of an Earnings Release (ER) or a general regulatory/investor update. Since it is not a full annual report (10-K), a transcript (CT), or a formal dividend notice (DIV), and it focuses on key results rather than just announcing a future report (RPA), the best fit among the provided options is the Earnings Release (ER) category, as clinical trial updates often accompany or substitute for traditional quarterly earnings highlights when a company is pre-revenue or focused on drug development milestones. It is a major operational announcement. Q2 2016
2016-04-04 English
CP FR
Regulatory Filings Classification · 95% confidence The document is an announcement from AB Science, dated April 4th, stating that the interim analysis of its Phase 3 study for masitinib in Amyotrophic Lateral Sclerosis (ALS) was positive. It details the study design, the primary and secondary endpoints (ALSFRS-R score, FVC, CAFS), the statistical success criteria, and quotes management regarding next steps (discussing filing for market authorization with EMA and FDA). This content is characteristic of an initial release of key financial/clinical results, often preceding the full detailed report. Since it announces the positive outcome of a clinical trial analysis and mentions next steps for regulatory filing, it aligns best with an Earnings Release (ER) if it were quarterly results, but since it is a major clinical trial milestone announcement, it functions similarly as a key performance indicator update. However, given the specific definitions, this is a major announcement of clinical trial success, which is often released as an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses purely on the positive clinical trial result and its implications, and is not a full financial report (10-K/IR) or a presentation (IP), the closest fit among the provided options for a major, time-sensitive operational/clinical update is the Earnings Release (ER), which often encompasses significant operational milestones beyond just revenue/profit figures in the biotech/pharma sector, or RNS as a general regulatory announcement. Given the structure and focus on announcing a key milestone ('AB Science announces that the interim analysis... is positive'), ER is a strong candidate, but RNS is the safest fallback for non-standard regulatory news. Since it is a specific, positive clinical trial result announcement, and not a general regulatory filing, I will lean towards ER as the functional equivalent of a major operational update, or RNS if ER is strictly interpreted as financial results. Given the context of a major clinical success announcement, which drives investor interest significantly, ER is often used for this type of news. However, RNS is the most general category for non-standard announcements. Let's re-evaluate: It is a press release announcing a major clinical trial success. This is typically classified as a Regulatory Filing (RNS) if it doesn't fit ER (which usually covers quarterly financials) or IR (Interim Report). Since it is a press release announcing a milestone, RNS is the most appropriate general regulatory announcement category.
2016-04-04 French
AB Science EN
Regulatory Filings Classification · 95% confidence The document is a press release from AB Science dated March 10, 2016, announcing the publication of four independent, peer-reviewed articles highlighting the potential of their drug, masitinib, in neurological diseases. It details the contents and citations of these external publications. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). It is an announcement intended for investors and the public regarding scientific developments and external validation of their research pipeline. Since it is an announcement about scientific/research progress rather than a mandatory financial filing or a specific management/governance update, it best fits the general 'Regulatory Filings' (RNS) category as a broad corporate communication, or potentially an Investor Presentation (IP) if it were structured as a slide deck, but given the format, RNS is the most appropriate catch-all for non-standard, non-financial-result-focused press releases.
2016-03-10 English
AB Science EN
Investor Presentation Classification · 95% confidence The document is a press release from AB Science SA, dated March 10, 2016, announcing that four independent, peer-reviewed publications highlight the potential of their drug candidate, masitinib, in neurological and neurodegenerative diseases. It details the findings of these publications and provides context about the drug and the company. This type of announcement, focusing on research updates, clinical trial progress (mentioning Phase 3 futility tests), and scientific literature, is characteristic of an Investor Presentation (IP) or a general press release related to R&D progress. Since it is not a formal regulatory filing like a 10-K, a quarterly report (IR), or a formal earnings release (ER), and it serves to inform investors about strategic developments and scientific validation, 'Investor Presentation' (IP) is the most fitting category, although it is structured as a press release summarizing external validation. Given the detailed scientific and clinical context provided to support the investment case, IP is preferred over the generic RNS.
2016-03-10 French
AB Science FR
Share Issue/Capital Change Classification · 95% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly Information Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital). It explicitly references Article 221-1 point 2 f and 223-16 of the AMF General Regulation (Autorité des Marchés Financiers). This structure, providing a monthly update on the total number of shares and voting rights, is a specific regulatory disclosure in France. While it relates to capital structure, it is not a general financing announcement (CAP) or a share issue (SHA). It is a mandatory periodic disclosure regarding the capital base. Given the specific nature of reporting voting rights and share count monthly, and the lack of a perfect fit among the primary options, it most closely aligns with a specific regulatory filing update. However, since the provided definitions do not have a specific code for 'Monthly Voting Rights Disclosure', I must select the closest fit. It is a mandatory regulatory disclosure, but it is not a general 'Regulatory Filing' (RNS) as it is highly specific. It is not a Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Since it details the composition of the capital and voting rights, it is related to capital structure, but the primary purpose is regulatory reporting of the current count. Given the options, and recognizing this as a specific regulatory disclosure, RNS (Regulatory Filings - fallback) is often used for mandatory, non-core financial reports. However, since it is a direct report on the capital structure components (shares and voting rights), it has a strong link to capital changes, but it's a reporting requirement, not an action. I will classify this as a specific regulatory filing update that doesn't fit the other categories, leaning towards RNS as the best fit for a mandatory, periodic, non-financial report.
2016-03-03 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.